Michael A. Schwarzschild - Publications

Affiliations: 
Neurology Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States 

48 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu F, Dong X, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Mangone G, Growdon JH, Hung AY, ... Schwarzschild MA, et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nature Genetics. PMID 33958783 DOI: 10.1038/s41588-021-00847-6  0.4
2021 Mestre TA, Macklin EA, Ascherio A, Ferreira JJ, Lang AE, Schwarzschild MA. Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33942376 DOI: 10.1002/mds.28630  0.32
2021 Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease. 7: 16. PMID 33649343 DOI: 10.1038/s41531-021-00162-1  0.32
2020 Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, ... ... Schwarzschild MA, et al. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Annals of Clinical and Translational Neurology. PMID 33350601 DOI: 10.1002/acn3.51236  0.32
2020 Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson's disease among mutation carriers: A metabolomic study. Neurology. PMID 32999056 DOI: 10.1212/WNL.0000000000010863  0.32
2020 Hasimoglu YG, Chen X, Bakshi R, Schwarzschild MA, Macklin EA. Does Serum Urate Change as Parkinson's Disease Progresses? Journal of Parkinson's Disease. 10: 1571-1576. PMID 32773396 DOI: 10.3233/Jpd-202064  0.32
2020 Huh YE, Ruby Chiang MS, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, et al. β-Glucocerebrosidase Activity in -linked Parkinson's Disease: The Type of Mutation Matters. Neurology. PMID 32540937 DOI: 10.1212/Wnl.0000000000009989  0.4
2020 Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. Journal of Parkinson's Disease. 10: 505-510. PMID 32250320 DOI: 10.3233/Jpd-191882  0.4
2019 Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. PMID 31484712 DOI: 10.1212/Wnl.0000000000008194  0.32
2019 Bakshi R, Macklin EA, Schwarzschild MA. Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers". Annals of Neurology. 86: 326-327. PMID 31148194 DOI: 10.1002/Ana.25509  0.32
2019 Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, Zhang E, Chen X, Ascherio A, Schwarzschild MA. Higher urate in LRRK2 mutation carriers resistant to Parkinson's disease. Annals of Neurology. PMID 30761591 DOI: 10.1002/Ana.25436  0.32
2018 Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. 5: 1522-1533. PMID 30564619 DOI: 10.1002/Acn3.671  0.32
2018 Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. Ebiomedicine. PMID 30415890 DOI: 10.1016/J.Ebiom.2018.10.039  0.32
2018 Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. Ebiomedicine. PMID 29433982 DOI: 10.1016/J.Ebiom.2018.01.035  0.32
2016 Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26805433 DOI: 10.1002/Mds.26483  0.36
2016 Gao X, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. PMID 26764029 DOI: 10.1212/Wnl.0000000000002351  0.36
2015 Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Schwarzschild MA. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiology of Disease. PMID 26341543 DOI: 10.1016/J.Nbd.2015.08.022  0.36
2015 Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain : a Journal of Neurology. 138: 2659-71. PMID 26220939 DOI: 10.1093/Brain/Awv202  0.4
2015 Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. Plos One. 10: e0116919. PMID 25608039 DOI: 10.1371/Journal.Pone.0116919  0.36
2014 Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environmental Health : a Global Access Science Source. 13: 80. PMID 25294559 DOI: 10.1186/1476-069X-13-80  0.36
2014 Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Annals of Neurology. 76: 862-8. PMID 25257975 DOI: 10.1002/Ana.24281  0.36
2014 Schwarzschild MA, Macklin EA, Ascherio A. Urate and neuroprotection trials. The Lancet. Neurology. 13: 758. PMID 25030508 DOI: 10.1016/S1474-4422(14)70138-3  0.32
2014 Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort. Environmental Health Perspectives. 122: 933-8. PMID 24905870 DOI: 10.1289/Ehp.1307218  0.36
2014 Kachroo A, Schwarzschild MA. Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease. Brain Research. 1563: 103-9. PMID 24680743 DOI: 10.1016/J.Brainres.2014.03.031  0.36
2014 Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 37: 369-72. PMID 24497665 DOI: 10.5665/Sleep.3416  0.36
2014 McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. Plos One. 9: e86048. PMID 24465863 DOI: 10.1371/Journal.Pone.0086048  0.36
2014 Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. Jama Neurology. 71: 141-50. PMID 24366103 DOI: 10.1001/Jamaneurol.2013.5528  0.32
2014 Hung AY, Schwarzschild MA. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 34-46. PMID 24310604 DOI: 10.1007/S13311-013-0239-9  0.36
2013 Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, ... ... Schwarzschild MA, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 81: 1531-7. PMID 24068787 DOI: 10.1212/Wnl.0B013E3182A95818  0.36
2013 Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. Journal of Parkinson's Disease. 3: 231-9. PMID 24018336 DOI: 10.3233/Jpd-139000  0.36
2013 McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neuro-Degenerative Diseases. 12: 189-98. PMID 23467193 DOI: 10.1159/000346370  0.36
2013 Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 380-3. PMID 23339054 DOI: 10.1002/Mds.25319  0.36
2013 Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, Schwarzschild MA. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 110: 300-5. PMID 23248282 DOI: 10.1073/Pnas.1217296110  0.36
2013 Salamone JD, Collins-Praino LE, Pardo M, Podurgiel SJ, Baqi Y, Müller CE, Schwarzschild MA, Correa M. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 972-7. PMID 22947264 DOI: 10.1016/J.Euroneuro.2012.08.004  0.36
2013 Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomedical Chromatography : Bmc. 27: 122-9. PMID 22674671 DOI: 10.1002/Bmc.2760  0.36
2012 Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, Ascherio A. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1276-82. PMID 22927157 DOI: 10.1002/Mds.25076  0.36
2012 Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. Journal of Neurochemistry. 123: 172-81. PMID 22671773 DOI: 10.1111/J.1471-4159.2012.07820.X  0.36
2012 Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. Plos One. 7: e37331. PMID 22606360 DOI: 10.1371/Journal.Pone.0037331  0.36
2012 Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease. Annals of Neurology. 71: 278-82. PMID 22367999 DOI: 10.1002/Ana.22630  0.36
2012 Matos M, Augusto E, Santos-Rodrigues AD, Schwarzschild MA, Chen JF, Cunha RA, Agostinho P. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia. 60: 702-16. PMID 22298379 DOI: 10.1002/Glia.22290  0.36
2011 Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, ... ... Schwarzschild MA, et al. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2283-6. PMID 21953863 DOI: 10.1002/Mds.23934  0.36
2011 Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, Mayo T, Schwarzschild MA, Ascherio A. Obesity, diabetes, and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2253-9. PMID 21739472 DOI: 10.1002/Mds.23855  0.36
2011 Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1864-8. PMID 21538532 DOI: 10.1002/Mds.23741  0.36
2011 Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Deletion of adenosine A₁ or A(â‚‚A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Research. 1367: 310-8. PMID 20828543 DOI: 10.1016/J.Brainres.2010.08.099  0.36
2010 Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neuroscience Letters. 486: 161-5. PMID 20854878 DOI: 10.1016/J.Neulet.2010.09.043  0.36
2010 Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Progress in Brain Research. 183: 183-208. PMID 20696321 DOI: 10.1016/S0079-6123(10)83010-9  0.36
2010 Kachroo A, Irizarry MC, Schwarzschild MA. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Experimental Neurology. 223: 657-61. PMID 20188092 DOI: 10.1016/J.Expneurol.2010.02.007  0.36
2009 McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. Journal of Neuropathology and Experimental Neurology. 68: 515-24. PMID 19525899 DOI: 10.1097/Nen.0B013E3181A24B53  0.36
Show low-probability matches.